IL192019A - Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors - Google Patents
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitorsInfo
- Publication number
- IL192019A IL192019A IL192019A IL19201908A IL192019A IL 192019 A IL192019 A IL 192019A IL 192019 A IL192019 A IL 192019A IL 19201908 A IL19201908 A IL 19201908A IL 192019 A IL192019 A IL 192019A
- Authority
- IL
- Israel
- Prior art keywords
- compound
- salt
- mol
- pyrrolo
- pyrazol
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74990505P | 2005-12-13 | 2005-12-13 | |
| US81023106P | 2006-06-02 | 2006-06-02 | |
| US85062506P | 2006-10-10 | 2006-10-10 | |
| US85687206P | 2006-11-03 | 2006-11-03 | |
| US85940406P | 2006-11-16 | 2006-11-16 | |
| PCT/US2006/047369 WO2007070514A1 (en) | 2005-12-13 | 2006-12-12 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL192019A0 IL192019A0 (en) | 2008-12-29 |
| IL192019A true IL192019A (en) | 2014-04-30 |
Family
ID=37903501
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL192019A IL192019A (en) | 2005-12-13 | 2008-06-05 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| IL231992A IL231992A (en) | 2005-12-13 | 2014-04-08 | Theroaryl is transformed into pyrrolo [2, 3 – b] pyridines and pyrrolo [3,2 – b] primidines as genus kinase inhibitors |
| IL248938A IL248938A0 (en) | 2005-12-13 | 2016-11-13 | Heteroaryl-modified pyrrolo[3,2-b]pyridines and pyrrolo[3,2-b]pyrimidines as Janus kinase inhibitors |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL231992A IL231992A (en) | 2005-12-13 | 2014-04-08 | Theroaryl is transformed into pyrrolo [2, 3 – b] pyridines and pyrrolo [3,2 – b] primidines as genus kinase inhibitors |
| IL248938A IL248938A0 (en) | 2005-12-13 | 2016-11-13 | Heteroaryl-modified pyrrolo[3,2-b]pyridines and pyrrolo[3,2-b]pyrimidines as Janus kinase inhibitors |
Country Status (36)
| Country | Link |
|---|---|
| US (16) | US7598257B2 (OSRAM) |
| EP (10) | EP2348023B9 (OSRAM) |
| JP (4) | JP5017278B2 (OSRAM) |
| KR (4) | KR101391900B1 (OSRAM) |
| CN (4) | CN103214484B (OSRAM) |
| AR (1) | AR057995A1 (OSRAM) |
| AT (1) | ATE525374T1 (OSRAM) |
| AU (1) | AU2006326548B2 (OSRAM) |
| BE (1) | BE2013C014I2 (OSRAM) |
| BR (1) | BRPI0619817B8 (OSRAM) |
| CA (1) | CA2632466C (OSRAM) |
| CR (2) | CR10065A (OSRAM) |
| CY (8) | CY1112762T1 (OSRAM) |
| DK (7) | DK2474545T3 (OSRAM) |
| EA (3) | EA019504B1 (OSRAM) |
| EC (2) | ECSP088540A (OSRAM) |
| ES (10) | ES2612196T3 (OSRAM) |
| FR (2) | FR13C0007I2 (OSRAM) |
| HR (7) | HRP20110903T1 (OSRAM) |
| HU (7) | HUE041382T2 (OSRAM) |
| IL (3) | IL192019A (OSRAM) |
| LT (6) | LT2474545T (OSRAM) |
| LU (1) | LU92137I2 (OSRAM) |
| ME (1) | ME01312B (OSRAM) |
| MX (1) | MX346183B (OSRAM) |
| MY (2) | MY159449A (OSRAM) |
| NZ (2) | NZ569015A (OSRAM) |
| PL (7) | PL2455382T3 (OSRAM) |
| PT (7) | PT2474545T (OSRAM) |
| RS (7) | RS54181B9 (OSRAM) |
| SG (3) | SG10201506912RA (OSRAM) |
| SI (7) | SI1966202T1 (OSRAM) |
| TW (6) | TWI553008B (OSRAM) |
| UA (2) | UA116187C2 (OSRAM) |
| WO (1) | WO2007070514A1 (OSRAM) |
| ZA (1) | ZA200805165B (OSRAM) |
Families Citing this family (433)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005105814A1 (en) * | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| EP1928874A1 (en) * | 2005-09-16 | 2008-06-11 | AstraZeneca AB | Heterobicyclic compounds as glucokinase activators |
| US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
| KR101467723B1 (ko) * | 2005-11-01 | 2014-12-03 | 탈자진 인코포레이티드 | 키나제의 비-아릴 메타-피리미딘 억제제 |
| US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| SI1966202T1 (sl) * | 2005-12-13 | 2012-01-31 | Incyte Corp | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze |
| JP5140600B2 (ja) * | 2005-12-23 | 2013-02-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | オーロラキナーゼのアザインドール阻害薬 |
| JP5099005B2 (ja) * | 2006-04-03 | 2012-12-12 | アステラス製薬株式会社 | ヘテロ化合物 |
| EP2001884A1 (en) * | 2006-04-05 | 2008-12-17 | Vertex Pharmaceuticals, Inc. | Deazapurines useful as inhibitors of janus kinases |
| CA2668652C (en) | 2006-11-20 | 2018-06-12 | President And Fellows Of Harvard College | Inhibitors of voltage-gated ion channels for use in treating pain and pruritis |
| ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| EP4606378A3 (en) * | 2007-06-13 | 2025-11-05 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-( 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylprop anenitrile |
| EP2176249A2 (en) * | 2007-07-02 | 2010-04-21 | Boehringer Ingelheim International GmbH | New chemical compounds |
| WO2009032338A1 (en) * | 2007-09-09 | 2009-03-12 | University Of Florida Research Foundation | Apratoxin therapeutic agents: mechanism and methods of treatment |
| WO2009049028A1 (en) * | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| JP2011500806A (ja) * | 2007-10-25 | 2011-01-06 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
| JP5480813B2 (ja) * | 2007-11-16 | 2014-04-23 | インサイト・コーポレイション | Ｊａｎｕｓキナーゼ阻害剤としての置換複素環 |
| BRPI0908433A2 (pt) * | 2008-02-06 | 2019-09-24 | Novartis Ag | pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase |
| US20110105436A1 (en) * | 2008-03-10 | 2011-05-05 | Auckland Uniservices Limited | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| SG191660A1 (en) * | 2008-03-11 | 2013-07-31 | Incyte Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| JP2011518221A (ja) * | 2008-04-21 | 2011-06-23 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｊａｎｕｓキナーゼの阻害剤 |
| CA2722326A1 (en) * | 2008-04-24 | 2009-10-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| AR071717A1 (es) | 2008-05-13 | 2010-07-07 | Array Biopharma Inc | Pirrolo[2,3-b]piridinas inhibidoras de quinasas chk1 y chk2,composiciones farmaceuticas que las contienen,proceso para prepararlas y uso de las mismas en el tratamiento y prevencion del cancer. |
| JP2011525892A (ja) * | 2008-06-18 | 2011-09-29 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｊａｎｕｓキナーゼの阻害剤 |
| BRPI0909945A2 (pt) * | 2008-06-20 | 2015-07-28 | Genentech Inc | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinase em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" |
| BRPI0910021A2 (pt) * | 2008-06-20 | 2015-09-01 | Genentech Inc | "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase" |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| JOP20190230A1 (ar) * | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| US8765727B2 (en) * | 2009-01-23 | 2014-07-01 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| AU2010249380B2 (en) * | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
| UA106078C2 (uk) * | 2009-05-22 | 2014-07-25 | Інсайт Корпорейшн | 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ |
| CA2764885C (en) | 2009-06-08 | 2018-05-15 | Takeda Pharmaceutical Company Limited | Dihydropyrrolonaphtyridinone compounds as inhibitors of jak |
| BRPI1015135B1 (pt) | 2009-06-29 | 2021-08-03 | Incyte Holdings Corporation | Pirimidinonas inibidoras de pi3k, composição compreendendo tais compostos, bem como usos dos mesmos |
| EP3485881B1 (en) | 2009-07-10 | 2024-03-13 | President and Fellows of Harvard College | Permanently charged sodium and calcium channel blockers as anti-inflammatory agents |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| TW201113285A (en) * | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| US9029359B2 (en) | 2009-09-04 | 2015-05-12 | Biogen Idec Ma, Inc. | Heteroaryl Btk inhibitors |
| BR112012005382A2 (pt) * | 2009-09-10 | 2016-03-29 | Hoffmann La Roche | inibidores de jak |
| JP6012468B2 (ja) * | 2009-10-02 | 2016-10-25 | アヴェクシン エーエス | 抗炎症性２−オキソチアゾールおよび２−オキソオキサゾール |
| CN105541847B (zh) * | 2009-10-09 | 2019-08-16 | 因西特控股公司 | 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物 |
| US8389728B2 (en) * | 2009-11-06 | 2013-03-05 | The Arizona Board Of Regents | Pollen tube stimulants from Arabidopsis pistils |
| US20110207754A1 (en) * | 2010-02-18 | 2011-08-25 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
| WO2011109217A2 (en) * | 2010-03-02 | 2011-09-09 | Immunodiagnostics, Inc. | Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors |
| AU2015205858B2 (en) * | 2010-03-10 | 2017-04-13 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| SI2545045T1 (sl) | 2010-03-10 | 2016-05-31 | Incyte Holdings Corporation | Derivati piperidin-4-ila kot zaviralci JAK1 |
| CA2796388A1 (en) * | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
| WO2011133920A1 (en) | 2010-04-23 | 2011-10-27 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| MX338228B (es) | 2010-05-21 | 2016-04-08 | Incyte Corp | Formulacion topica para inhibidor de cinasas janus (jak). |
| EP2606051B1 (en) * | 2010-08-20 | 2016-10-05 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| CN103261169A (zh) * | 2010-09-24 | 2013-08-21 | 密歇根大学董事会 | 脱泛素酶抑制剂及其应用方法 |
| EP2632903A4 (en) | 2010-10-28 | 2014-11-26 | Viamet Pharmaceuticals Inc | METALLOENZYMHEMMERVERBINDUNGEN |
| WO2012060847A1 (en) | 2010-11-07 | 2012-05-10 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US8933085B2 (en) * | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| EA036970B1 (ru) * | 2010-11-19 | 2021-01-21 | Инсайт Холдингс Корпорейшн | Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1 |
| JP6097998B2 (ja) * | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
| CA2822070C (en) | 2010-12-20 | 2019-09-17 | Incyte Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| ES2543312T3 (es) | 2011-02-11 | 2015-08-18 | Batmark Limited | Componente para inhalador |
| PT2675451E (pt) * | 2011-02-18 | 2015-10-16 | Incyte Corp | Terapia de combinação com inibidores mtor/jak |
| EP2678316A2 (en) | 2011-02-24 | 2014-01-01 | Cephalon, Inc. | Substituted aromatic sulfur compounds and methods of their use |
| WO2012127506A1 (en) | 2011-03-22 | 2012-09-27 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| EP2710006A1 (en) * | 2011-05-17 | 2014-03-26 | Principia Biopharma Inc. | Azaindole derivatives as tyrosine kinase inhibitors |
| EP2720696B1 (en) | 2011-06-14 | 2016-05-25 | Novartis AG | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| WO2012177606A1 (en) | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| CN103732596B (zh) | 2011-07-08 | 2016-06-01 | 诺华股份有限公司 | 吡咯并嘧啶衍生物 |
| US9358229B2 (en) | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| DK3513793T3 (da) | 2011-09-02 | 2021-04-26 | Incyte Holdings Corp | Heterocyclylaminer som pi3k-inhibitorer |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| CA2849357A1 (en) * | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Acyclic cyanoethylpyrazoles as janus kinase inhibitors |
| SG11201401342VA (en) * | 2011-10-12 | 2014-09-26 | Array Biopharma Inc | 5,7-substituted-imidazo[1,2-c]pyrimidines |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| CN107898790B (zh) | 2011-11-30 | 2024-06-21 | 埃默里大学 | 用于治疗或预防逆转录病毒和其它病毒感染的抗病毒jak抑制剂 |
| US8993756B2 (en) * | 2011-12-06 | 2015-03-31 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| US20130310340A1 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| IN2014DN10670A (OSRAM) * | 2012-06-15 | 2015-08-28 | Concert Pharmaceuticals Inc | |
| MX367055B (es) | 2012-06-26 | 2019-08-02 | Del Mar Pharmaceuticals | El uso de una composición que comprende dianhidrogalactitol, diacetildianhidrogalactitol, y dibromodulcitol, y análogos o derivados de cada uno para el tratamiento de malignidades resistentes a inhibidores de tirosina cinasa. |
| US20150246043A1 (en) | 2012-07-27 | 2015-09-03 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
| JP6276762B2 (ja) * | 2012-08-02 | 2018-02-07 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | キナーゼ阻害剤として活性な置換ピロール類 |
| IN2015DN02008A (OSRAM) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| US20150284394A1 (en) * | 2012-10-26 | 2015-10-08 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| WO2014071031A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| IL297429A (en) * | 2012-11-15 | 2022-12-01 | Incyte Holdings Corp | Sustained release dosage forms of roxolitinib |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| JP6353460B2 (ja) * | 2012-12-06 | 2018-07-04 | バルーク エス．ブランバーグ インスティチュート | Ｈｂｖ感染に対する抗ウイルス剤としての官能化ベンズアミド誘導体 |
| US9260426B2 (en) | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| CA2899137C (en) | 2013-01-29 | 2021-07-13 | Avexxin As | Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds |
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| WO2014126037A1 (ja) * | 2013-02-12 | 2014-08-21 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子及び照明装置 |
| PT3489239T (pt) | 2013-03-06 | 2021-12-17 | Incyte Holdings Corp | Processos e intermediários para a preparação de um inibidor de jak |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| TR201905814T4 (tr) | 2013-05-17 | 2019-05-21 | Incyte Corp | Jak inhibitörü olarak bipirazol tuzu. |
| CN114010611B (zh) | 2013-08-07 | 2023-11-28 | 因赛特控股公司 | Jak1抑制剂的持续释放剂型 |
| AU2014309017A1 (en) * | 2013-08-20 | 2016-03-10 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated C-reactive protein levels |
| EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| WO2015057695A1 (en) * | 2013-10-15 | 2015-04-23 | Bohan Jin | Novel compositions, uses and methods for their preparation |
| KR20160090814A (ko) | 2013-11-27 | 2016-08-01 | 노파르티스 아게 | Jak, cdk 및 pim의 억제제를 포함하는 조합 요법 |
| EP3318565B1 (en) | 2013-12-05 | 2021-04-14 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| CN110229159B (zh) * | 2013-12-18 | 2021-08-24 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| KR102261733B1 (ko) * | 2013-12-18 | 2021-06-04 | 콘서트 파마슈티컬즈, 인크. | 룩소리티닙의 중수소화된 유도체 |
| JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
| JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
| WO2015131031A1 (en) * | 2014-02-28 | 2015-09-03 | Incyte Corporation | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| US9340540B2 (en) | 2014-02-28 | 2016-05-17 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| US20150259420A1 (en) | 2014-03-14 | 2015-09-17 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
| EP3795152A1 (en) | 2014-04-08 | 2021-03-24 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| JP2017514832A (ja) | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| RU2564891C1 (ru) * | 2014-05-27 | 2015-10-10 | Александр Александрович Кролевец | Способ получения нанокапсул цитокининов |
| EP4233870A3 (en) * | 2014-05-28 | 2024-01-24 | Onco Tracker, Inc. | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EP3169686A4 (en) * | 2014-07-14 | 2018-01-24 | Signal Pharmaceuticals, LLC | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| TW201618772A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑及／或ｂｃｌ－２抑制劑之治療組合物 |
| PL3179992T3 (pl) | 2014-08-11 | 2022-08-16 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora BTK, inhibitora PD-1 i/lub inhibitora PD-L1 |
| AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
| CN106715456B (zh) | 2014-08-12 | 2023-08-29 | 莫纳什大学 | 定向淋巴的前药 |
| WO2016026974A1 (en) * | 2014-08-21 | 2016-02-25 | Ratiopharm Gmbh | Oxalate salt of ruxolitinib |
| US20170281624A1 (en) | 2014-09-13 | 2017-10-05 | Novartis Ag | Combination therapies of alk inhibitors |
| CN105524067A (zh) * | 2014-09-28 | 2016-04-27 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
| EP3662903A3 (en) | 2014-10-03 | 2020-10-14 | Novartis AG | Combination therapies |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| ES2952717T3 (es) | 2014-10-14 | 2023-11-03 | Novartis Ag | Moléculas de anticuerpos contra PD-L1 y usos de las mismas |
| WO2016063294A2 (en) * | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof |
| ES2870449T3 (es) | 2014-10-29 | 2021-10-27 | Bicyclerd Ltd | Ligandos peptídicos bicíclicos específicos de MT1-MMP |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| CZ2014773A3 (cs) | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| CN105777754B (zh) * | 2014-12-16 | 2019-07-26 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
| TWI744225B (zh) | 2015-02-27 | 2021-11-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶２（ｔｙｋ２）抑制劑及其用途 |
| MX373232B (es) | 2015-02-27 | 2020-05-08 | Incyte Holdings Corp | Sales del inhibidor fosfoinositida 3-cinasa (pi3k) y procesos para su preparación. |
| HK1248603A1 (zh) | 2015-03-10 | 2018-10-19 | Aduro Biotech, Inc. | 用於活化"干扰素基因的刺激剂"依懒性信号传导的组合物和方法 |
| KR101859170B1 (ko) * | 2015-04-17 | 2018-05-17 | 광주과학기술원 | 트리아졸 화합물 및 이의 용도 |
| WO2016173484A1 (zh) * | 2015-04-29 | 2016-11-03 | 南京明德新药研发股份有限公司 | Jak抑制剂 |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| WO2016183063A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Crystalline forms of a pi3k inhibitor |
| WO2016183071A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Hetero-tricyclic compounds and their use for the treatment of cancer |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CZ2015496A3 (cs) | 2015-07-14 | 2017-01-25 | Zentiva, K.S. | Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| PT3317301T (pt) | 2015-07-29 | 2021-07-09 | Novartis Ag | Terapias de associação compreendendo moléculas de anticorpo contra lag-3 |
| JP6878405B2 (ja) | 2015-07-29 | 2021-05-26 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子を含む組み合わせ治療 |
| RU2018107695A (ru) | 2015-08-03 | 2019-09-05 | Президент Энд Феллоуз Оф Гарвард Колледж | Заряженные блокаторы ионных каналов и способы их применения |
| US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
| WO2017035366A1 (en) | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| EP4327809A3 (en) | 2015-09-02 | 2024-04-17 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors and uses thereof |
| CN114031658A (zh) | 2015-09-08 | 2022-02-11 | 莫纳什大学 | 定向淋巴的前药 |
| US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| RS64114B1 (sr) | 2015-10-23 | 2023-04-28 | Navitor Pharm Inc | Modulatori interakcije sestrin-gator2 i nјihova upotreba |
| EP4046655A1 (en) | 2015-11-03 | 2022-08-24 | Janssen Biotech, Inc. | Antibodies specifically binding pd-1 and their uses |
| TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之雜環化合物 |
| AU2016354009B2 (en) | 2015-11-09 | 2021-05-20 | R.P. Scherer Technologies, Llc | Anti-CD22 antibody-maytansine conjugates and methods of use thereof |
| RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
| US11370792B2 (en) | 2015-12-14 | 2022-06-28 | Raze Therapeutics, Inc. | Caffeine inhibitors of MTHFD2 and uses thereof |
| CN108368115B (zh) * | 2015-12-15 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的盐 |
| JP2019503349A (ja) | 2015-12-17 | 2019-02-07 | ノバルティス アーゲー | Ｐｄ−１に対する抗体分子およびその使用 |
| JP2019502695A (ja) | 2015-12-17 | 2019-01-31 | ノバルティス アーゲー | ＰＤ−１に対する抗体分子とＣ−Ｍｅｔ阻害剤との組合せおよびその使用 |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| CN108699063B (zh) * | 2015-12-31 | 2020-06-26 | 正大天晴药业集团股份有限公司 | 一种芦可替尼的合成工艺 |
| DK3402515T3 (da) | 2016-01-12 | 2021-11-15 | Oncotracker Inc | Forbedrede fremgangsmåder til monitorering af et individs immunstatus |
| CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
| ES2877200T3 (es) | 2016-01-26 | 2021-11-16 | Hangzhou Bangshun Pharmaceutical Co Ltd | Derivado azacíclico de cinco miembros de pirrolopirimidina y aplicación del mismo |
| CN105541891B (zh) * | 2016-02-04 | 2017-11-28 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
| EP3884939B1 (en) | 2016-03-09 | 2023-10-25 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| EP4234552A3 (en) | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| IL293496B2 (en) | 2016-03-28 | 2023-05-01 | Incyte Corp | Pyrrolotriazine compounds as TAM inhibitors |
| WO2017177230A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| CN109069493A (zh) | 2016-05-04 | 2018-12-21 | 康塞特医药品有限公司 | 用氘代jak抑制剂治疗脱毛障碍 |
| AU2017272505B9 (en) | 2016-06-01 | 2021-10-28 | Bayer Pharma Aktiengesellschaft | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals |
| CN107513069A (zh) * | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
| CN107759600A (zh) * | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
| CN107513067A (zh) * | 2016-06-16 | 2017-12-26 | 北京赛林泰医药技术有限公司 | 含有取代环戊基的吡咯并嘧啶化合物 |
| EP3471726A4 (en) | 2016-06-21 | 2019-10-09 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| JP7054529B2 (ja) | 2016-06-21 | 2022-04-14 | エックス４ ファーマシューティカルズ， インコーポレイテッド | Ｃｘｃｒ４阻害剤およびその使用 |
| CN109641838A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| AU2017287762C1 (en) | 2016-06-30 | 2020-04-23 | Daewoong Pharmaceutical Co., Ltd. | Pyrazolopyrimidine derivatives as kinase inhibitor |
| WO2018009466A1 (en) | 2016-07-05 | 2018-01-11 | Aduro Biotech, Inc. | Locked nucleic acid cyclic dinucleotide compounds and uses thereof |
| EP3492468B1 (en) * | 2016-07-26 | 2022-02-23 | Suzhou Longbiotech Pharmaceuticals Co., Ltd. | Heterocyclic compound as jak inhibitor, and salts and therapeutic use thereof |
| KR20190035925A (ko) | 2016-08-24 | 2019-04-03 | 아르퀼 인코포레이티드 | 아미노-피롤로피리미디논 화합물 및 이의 사용 방법 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| IT201600092051A1 (it) * | 2016-09-13 | 2018-03-13 | Alessandro Antonelli | Composto medicale per il trattamento di tumori della tiroide |
| TWI825663B (zh) | 2016-10-14 | 2023-12-11 | 美商林伯士拉克許米公司 | Tyk2抑制劑及其用途 |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| US10414727B2 (en) | 2016-11-08 | 2019-09-17 | Navitor Pharmaceuticals, Inc. | Phenyl amino piperidine mTORC inhibitors and uses thereof |
| EP3548005A4 (en) | 2016-11-29 | 2020-06-17 | Puretech Health LLC | Exosomes for delivery of therapeutic agents |
| US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
| RU2644155C1 (ru) * | 2016-12-12 | 2018-02-08 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ |
| EP3559018A1 (en) | 2016-12-23 | 2019-10-30 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| EA039352B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение |
| AR111233A1 (es) | 2017-03-08 | 2019-06-19 | Nimbus Lakshmi Inc | Inhibidores de tyk2, usos y métodos para la producción de los mismos |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| JP7179015B2 (ja) | 2017-04-26 | 2022-11-28 | ナビター ファーマシューティカルズ， インコーポレイテッド | Ｓｅｓｔｒｉｎ－ＧＡＴＯＲ２相互座用のモジュレーターおよびその使用 |
| EP3615550A1 (en) | 2017-04-27 | 2020-03-04 | BicycleTx Limited | Bicyclic peptide ligands and uses thereof |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| MX2019014054A (es) | 2017-05-23 | 2020-02-05 | Theravance Biopharma R&D Ip Llc | Profarmacos de glucuronida de inhibidores de la cinasa janus. |
| EP3639028B1 (en) | 2017-06-13 | 2025-10-15 | Onco Tracker, Inc. | Diagnostic, prognostic, and monitoring methods for breast cancer |
| PE20200717A1 (es) | 2017-06-22 | 2020-07-21 | Novartis Ag | Moleculas de anticuerpo que se unen a cd73 y usos de las mismas |
| US20200172628A1 (en) | 2017-06-22 | 2020-06-04 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| US10899798B2 (en) | 2017-06-26 | 2021-01-26 | Bicyclerd Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| CN107298680A (zh) * | 2017-07-12 | 2017-10-27 | 海门华祥医药科技有限公司 | 一种4‑氯‑7‑氮杂吲哚的生产工艺 |
| DK3658557T3 (da) | 2017-07-28 | 2024-07-29 | Takeda Pharmaceuticals Co | Tyk2-inhibitorer og anvendelser deraf |
| WO2019025811A1 (en) | 2017-08-04 | 2019-02-07 | Bicycletx Limited | SPECIFIC BICYCLIC PEPTIDE LIGANDS OF CD137 |
| EP3668887A1 (en) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| EP3668550A1 (en) | 2017-08-14 | 2020-06-24 | Bicyclerd Limited | Bicyclic peptide ligand prr-a conjugates and uses thereof |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| AU2018324037A1 (en) | 2017-08-29 | 2020-04-16 | Monash University | Lymphatic system-directing lipid prodrugs |
| EP3684366A4 (en) | 2017-09-22 | 2021-09-08 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| JP7366031B2 (ja) | 2017-09-22 | 2023-10-20 | カイメラ セラピューティクス， インコーポレイテッド | タンパク質分解剤およびそれらの使用 |
| SMT202200011T1 (it) | 2017-09-27 | 2022-03-21 | Incyte Corp | Sali di derivati di pirrolotriazina utili come inibitori di tam |
| CN109651424B (zh) * | 2017-10-11 | 2021-01-22 | 新发药业有限公司 | 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法 |
| WO2019090143A1 (en) * | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same |
| CN119119039A (zh) | 2017-11-03 | 2024-12-13 | 阿克拉瑞斯治疗股份有限公司 | 被取代的吡咯并吡啶jak抑制剂及其制造方法和使用方法 |
| KR102034538B1 (ko) | 2017-11-28 | 2019-10-21 | 주식회사한국파마 | Jak 저해제 화합물, 및 이의 제조방법 |
| US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| WO2019126378A1 (en) | 2017-12-19 | 2019-06-27 | Ariya Therapeutics, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| EP3737666A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES |
| EP3737675A4 (en) | 2018-01-12 | 2022-01-05 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| IL301089A (en) | 2018-01-29 | 2023-05-01 | Vertex Pharma | GCN2 inhibitors and their uses |
| BR112020015396A2 (pt) | 2018-01-29 | 2020-12-08 | Merck Patent Gmbh | Inididores de gcn2 e usos dos mesmos |
| UA127488C2 (uk) | 2018-01-30 | 2023-09-06 | Інсайт Корпорейшн | Способи одержання (1-(3-фтор-2-(трифторметил)ізонікотиноїл)піперидин-4-ону) |
| JP7736431B2 (ja) | 2018-02-16 | 2025-09-09 | インサイト・コーポレイション | サイトカイン関連障害を治療するためのｊａｋ１経路阻害薬 |
| CA3091775A1 (en) | 2018-02-23 | 2019-08-29 | Bicycletx Limited | Multimeric bicyclic peptide ligands |
| KR102526964B1 (ko) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Hbv 복제 억제제로서의 치환된 피롤리진 화합물 |
| WO2019169001A1 (en) | 2018-02-27 | 2019-09-06 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of tcr-nck interaction |
| AU2019229885A1 (en) | 2018-03-08 | 2020-09-10 | Anna Rita Franco MIGLIACCIO | Use of an anti-P-selectin antibody |
| CN110357887B (zh) * | 2018-03-26 | 2022-09-16 | 武汉誉祥医药科技有限公司 | 取代的7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| EP3775284A1 (en) | 2018-03-30 | 2021-02-17 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| PT3773593T (pt) | 2018-03-30 | 2024-06-25 | Incyte Corp | Tratamento da hidradenite supurativa com inibidores de jak |
| CN112567247A (zh) | 2018-04-13 | 2021-03-26 | 因赛特公司 | 用于移植物抗宿主病的生物标志物 |
| ES2969982T3 (es) | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
| HUE058746T2 (hu) | 2018-04-24 | 2022-09-28 | Merck Patent Gmbh | Antiproliferációs vegyületek és felhasználásuk |
| AR126019A1 (es) | 2018-05-30 | 2023-09-06 | Novartis Ag | Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| MA52761A (fr) | 2018-06-01 | 2021-04-14 | Incyte Corp | Schéma posologique destiné au traitement de troubles liés à la pi3k |
| EP3805219A4 (en) * | 2018-06-06 | 2022-03-23 | Gengle Therapeutics, Inc. | PYRAZOLOPYRIMIDI DERIVATIVE, ITS USE AND PHARMACEUTICAL COMPOSITION |
| HUE067446T2 (hu) | 2018-06-15 | 2024-10-28 | Janssen Pharmaceutica Nv | Rapamicin analógok és alkalmazásaik |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| EP3813800B1 (en) | 2018-06-29 | 2025-05-07 | Incyte Corporation | Formulations of an axl/mer inhibitor |
| JP6830460B2 (ja) * | 2018-07-05 | 2021-02-17 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| KR102612513B1 (ko) | 2018-07-31 | 2023-12-12 | 록쏘 온콜로지, 인코포레이티드 | (s)-5-아미노-3-(4-((5-플루오로-2-메톡시벤즈아미도)메틸)페닐)-1-(1,1,1-트리플루오로프로판-2-일)-1h-피라졸-4-카르복스아미드의 분무-건조된 분산물 및 제제 |
| US11021482B2 (en) | 2018-08-10 | 2021-06-01 | Adaris Therapeutics, Inc. | Pyrrolopyrimidine ITK inhibitors |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| JP2022500499A (ja) | 2018-09-07 | 2022-01-04 | ピク セラピューティクス， インコーポレイテッド | Ｅｉｆ４ｅ阻害剤およびその使用 |
| JP7619951B2 (ja) | 2018-10-15 | 2025-01-22 | 武田薬品工業株式会社 | Ｔｙｋ２阻害剤およびその使用 |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| IL282643B2 (en) | 2018-10-31 | 2025-08-01 | Incyte Corp | A selective jak1 inhibitor for use in a method of treating hematological disease |
| CN113271938A (zh) | 2018-11-30 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| PH12021500026A1 (en) | 2018-11-30 | 2022-05-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CN109394768B (zh) * | 2018-12-10 | 2019-08-23 | 牡丹江医学院 | 一种治疗湿疹的药物及其制备方法 |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| JP2022515198A (ja) | 2018-12-19 | 2022-02-17 | アレイ バイオファーマ インコーポレイテッド | ＦＧＦＲチロシンキナーゼの阻害剤としての置換ピラゾロ［１，５－ａ］ピリジン化合物 |
| WO2020131674A1 (en) | 2018-12-19 | 2020-06-25 | Array Biopharma Inc. | 7-((3,5-dimethoxyphenyl)amino)quinoxaline derivatives as fgfr inhibitors for treating cancer |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| JP2022514618A (ja) | 2018-12-21 | 2022-02-14 | バイスクルテクス・リミテッド | Ｐｄ－ｌ１に特異的な二環式ペプチドリガンド |
| KR20210107069A (ko) | 2018-12-21 | 2021-08-31 | 다이이찌 산쿄 가부시키가이샤 | 항체-약물 컨쥬게이트와 키나아제 저해제의 조합 |
| CN113348021B (zh) | 2019-01-23 | 2025-07-11 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| CN111620873B (zh) * | 2019-02-28 | 2021-12-28 | 沈阳药科大学 | 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途 |
| SG11202109563WA (en) | 2019-03-05 | 2021-09-29 | Incyte Corp | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| JP7692834B2 (ja) | 2019-03-11 | 2025-06-16 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| CA3129111A1 (en) | 2019-03-11 | 2020-09-17 | Bridget M. Cole | Charged ion channel blockers and methods for use |
| EP3937934A4 (en) | 2019-03-11 | 2022-11-09 | Nocion Therapeutics, Inc. | ESTER SUBSTITUTED ION CHANNEL BLOCKERS AND METHODS OF USE |
| US10786485B1 (en) | 2019-03-11 | 2020-09-29 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| TW202102222A (zh) | 2019-03-19 | 2021-01-16 | 美商英塞特公司 | 白斑病之生物標記物 |
| MX2021009863A (es) | 2019-03-21 | 2021-11-12 | Onxeo | Una molecula dbait en combinacion con inhibidor de quinasa para el tratamiento del cancer. |
| JP2022528887A (ja) | 2019-04-02 | 2022-06-16 | バイスクルテクス・リミテッド | バイシクルトキシンコンジュゲートおよびその使用 |
| US11485750B1 (en) | 2019-04-05 | 2022-11-01 | Kymera Therapeutics, Inc. | STAT degraders and uses thereof |
| CA3134750A1 (en) | 2019-04-24 | 2020-10-29 | Jingdan Hu | A 7h-pyrrolo[2,3-d]pyrimidine jak-inhibitor |
| EP3962897A4 (en) | 2019-05-02 | 2022-12-14 | Aclaris Therapeutics, Inc. | SUBSTITUTED PYRROLOPYRIDINES AS JAK INHIBITORS |
| KR102286372B1 (ko) | 2019-05-27 | 2021-08-05 | 주식회사한국파마 | Jak 저해제 화합물, 및 이를 포함하는 의약 조성물 |
| CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
| JP7592029B2 (ja) * | 2019-05-28 | 2024-11-29 | マンカインド ファーマ リミテッド | ヤヌスキナーゼ１の阻害のための新規化合物 |
| BR112021024224A2 (pt) | 2019-05-31 | 2022-04-26 | Ikena Oncology Inc | Inibidores de tead e usos dos mesmos |
| US12521438B2 (en) | 2019-06-10 | 2026-01-13 | Kymera Therapeutics, Inc. | SMARCA degraders and uses thereof |
| US20200405627A1 (en) | 2019-06-10 | 2020-12-31 | Incyte Corporation | Topical treatment of vitiligo by a jak inhibitor |
| MX2022000016A (es) | 2019-06-27 | 2022-02-24 | Crispr Therapeutics Ag | Uso de linfocitos t con receptor de antigeno quimerico e inhibidores de linfocitos citoliticos naturales para el tratamiento del cancer. |
| CN110305140B (zh) | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| WO2021022178A1 (en) * | 2019-07-31 | 2021-02-04 | Aclaris Therapeutics, Inc. | Substituted sulfonamide pyrrolopyridines as jak inhibitors |
| WO2021022076A1 (en) * | 2019-08-01 | 2021-02-04 | St. Jude Children's Research Hospital | Molecules and methods related to treatment of uncontrolled cellular proliferation |
| EP4028385A4 (en) | 2019-09-11 | 2023-11-08 | Vincere Biosciences, Inc. | USP30 INHIBITORS AND USES THEREOF |
| PH12022550605A1 (en) | 2019-09-13 | 2023-09-25 | Nimbus Saturn Inc | Hpk1 antagonists and uses thereof |
| JP2022547311A (ja) | 2019-09-16 | 2022-11-11 | ノバルティス アーゲー | 骨髄線維症の治療のためのｍｄｍ２阻害剤の使用 |
| JP2022548627A (ja) | 2019-09-16 | 2022-11-21 | ノバルティス アーゲー | 骨髄線維症の治療のための、高親和性のリガンドを遮断するヒト化抗ｔ細胞免疫グロブリンドメイン及びムチンドメイン３（ｔｉｍ－３）ｉｇｇ４抗体の使用 |
| WO2021053559A1 (en) | 2019-09-18 | 2021-03-25 | Novartis Ag | Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies |
| AU2020356575A1 (en) | 2019-09-27 | 2022-04-14 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CN110538183B (zh) * | 2019-10-09 | 2021-05-04 | 吉林大学 | 一种预防和治疗小儿湿疹的组合物及其制备方法 |
| JP2022551649A (ja) | 2019-10-10 | 2022-12-12 | インサイト・コーポレイション | 移植片対宿主病のバイオマーカー |
| WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| WO2021076124A1 (en) | 2019-10-16 | 2021-04-22 | Incyte Corporation | Use of jak1 inhibitors for the treatment of cutaneous lupus erythematosus and lichen planus (lp) |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| MX2022005215A (es) | 2019-11-01 | 2022-06-08 | Navitor Pharm Inc | Metodos de tratamiento que usan un modulador de la diana mecanicista del complejo 1 de rapamicina (mtorc1). |
| JP7513713B2 (ja) | 2019-11-06 | 2024-07-09 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| IL292505A (en) | 2019-11-06 | 2022-06-01 | Nocion Therapeutics Inc | Charged ion channel blockers and methods of use |
| WO2021089791A1 (en) | 2019-11-08 | 2021-05-14 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| IL293085A (en) | 2019-11-22 | 2022-07-01 | Incyte Corp | Combination therapy comprising an alk2 inhibitor and a jak2 inhibitor |
| IL293549A (en) | 2019-12-05 | 2022-08-01 | Anakuria Therapeutics Inc | Rapamycin analogs and uses thereof |
| EP4076520A4 (en) | 2019-12-17 | 2024-03-27 | Kymera Therapeutics, Inc. | IRAQ DEGRADATION AGENTS AND THEIR USES |
| US11591332B2 (en) | 2019-12-17 | 2023-02-28 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| CN115297931A (zh) | 2019-12-23 | 2022-11-04 | 凯麦拉医疗公司 | Smarca降解剂和其用途 |
| JP2023509452A (ja) | 2020-01-03 | 2023-03-08 | バーグ エルエルシー | がんを処置するためのｕｂｅ２ｋモジュレータとしての多環式アミド |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| US20210268115A1 (en) | 2020-02-05 | 2021-09-02 | Puretech Lyt, Inc. | Lipid prodrugs of neurosteroids |
| CN111728975A (zh) * | 2020-02-25 | 2020-10-02 | 广东省检迅检测科技有限公司 | 用于减少运动损伤和促进运动损伤修复的组合物 |
| CN115515685B (zh) | 2020-03-03 | 2025-04-08 | 皮克医疗公司 | Eif4e抑制剂及其用途 |
| CN115697343A (zh) | 2020-03-06 | 2023-02-03 | 因赛特公司 | 包含axl/mer和pd-1/pd-l1抑制剂的组合疗法 |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| AU2021236130A1 (en) | 2020-03-11 | 2022-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| EP3892280A3 (en) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
| WO2021209563A1 (en) | 2020-04-16 | 2021-10-21 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| PH12022553277A1 (en) | 2020-06-02 | 2024-02-19 | Incyte Corp | Processes of preparing a jak1 inhibitor |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| AU2020451061A1 (en) | 2020-06-03 | 2022-12-15 | Incyte Corporation | Combination of ruxolitinib with INCB057643 for treatment of myeloproliferative neoplasms |
| BR112022024729A2 (pt) | 2020-06-05 | 2023-02-28 | Kinnate Biopharma Inc | Inibidores de quinases do receptor do fator de crescimento de fibroblastos |
| US20220023344A1 (en) | 2020-06-26 | 2022-01-27 | Crispr Therapeutics Ag | Allogeneic cell therapy of acute lymphoblastic leukemia using genetically engineered t cells targeting cd19 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| US11751108B2 (en) * | 2020-08-05 | 2023-09-05 | Qualcomm Incorporated | Execution of reduced signaling handover |
| CN116348467A (zh) * | 2020-08-12 | 2023-06-27 | 康塞特医药品有限公司 | 用于制备对映异构体富集的jak抑制剂的方法 |
| CA3186504A1 (en) | 2020-08-17 | 2022-02-24 | Stephen J. Blakemore | Bicycle conjugates specific for nectin-4 and uses thereof |
| CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
| CR20230129A (es) | 2020-08-18 | 2023-07-13 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
| JP2023541052A (ja) * | 2020-09-16 | 2023-09-27 | エクセソ バイオファーマ カンパニー リミテッド | ピリミドピリミジノン化合物及びそれを含む薬剤学的組成物 |
| CN116261447A (zh) | 2020-09-16 | 2023-06-13 | 因赛特公司 | 局部治疗白癜风 |
| WO2022072814A1 (en) | 2020-10-02 | 2022-04-07 | Incyte Corporation | Topical ruxolitinib for treating lichen planus |
| WO2022074600A1 (en) | 2020-10-08 | 2022-04-14 | Novartis Ag | Use of an erk inhibitor for the treatment of myelofibrosis |
| EP4225316A1 (en) | 2020-10-08 | 2023-08-16 | Novartis AG | Use of an erk inhibitor for the treatment of myelofibrosis |
| TW202233612A (zh) | 2020-10-23 | 2022-09-01 | 美商林伯士科羅索公司 | Ctps1抑制劑及其用途 |
| CN114437079B (zh) * | 2020-10-30 | 2024-11-01 | 杭州邦顺制药有限公司 | 吡咯嘧啶五元氮杂环化合物的晶型 |
| KR102551758B1 (ko) | 2020-11-30 | 2023-07-05 | 주식회사한국파마 | 신규한 jak 특이 저해제 화합물, 및 이의 제조방법 |
| KR20230131189A (ko) | 2020-12-02 | 2023-09-12 | 이케나 온콜로지, 인코포레이티드 | Tead 억제제 및 이의 용도 |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| LT4255442T (lt) | 2020-12-04 | 2025-07-25 | Incyte Corporation | Jak inhibitorius su vitamino d analogu, skirtas odos ligų gydymui |
| AU2021396231A1 (en) | 2020-12-08 | 2023-06-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| US11827657B2 (en) | 2020-12-18 | 2023-11-28 | Boehringer Ingelheim Animal Health USA Inc. | Boron containing pyrazole compounds, compositions comprising them, methods and uses thereof |
| KR20230143632A (ko) | 2020-12-30 | 2023-10-12 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| AU2022206313A1 (en) | 2021-01-11 | 2023-08-31 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| EP4284802A4 (en) * | 2021-02-01 | 2025-01-01 | Janssen Biotech, Inc. | SMALL MOLECULE INHIBITORS OF SALT-INDUCIBLE KINASES |
| AU2022216810A1 (en) | 2021-02-02 | 2023-08-24 | Liminal Biosciences Limited | Gpr84 antagonists and uses thereof |
| MX2023009059A (es) | 2021-02-02 | 2023-09-15 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| EP4291235A4 (en) | 2021-02-12 | 2025-01-08 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| US11773103B2 (en) | 2021-02-15 | 2023-10-03 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| IL304907A (en) | 2021-02-15 | 2023-10-01 | Kymera Therapeutics Inc | Irak4 degraders and uses thereof |
| JP2024507938A (ja) | 2021-02-25 | 2024-02-21 | インパクト バイオメディシンズ インコーポレイテッド | 骨髄線維症の治療としてのｂｅｔ阻害剤の使用 |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| EP4313989A4 (en) | 2021-03-29 | 2025-03-05 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| BR112023020781A2 (pt) | 2021-04-09 | 2023-12-19 | Nimbus Clio Inc | Moduladores de cbl-b e usos dos mesmos |
| AU2022258968A1 (en) | 2021-04-16 | 2023-10-19 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| LT4333840T (lt) | 2021-05-03 | 2026-01-12 | Incyte Corporation | Jak1 kelio inhibitoriai, skirti mazgelinio niežulio gydymui |
| TW202309030A (zh) | 2021-05-07 | 2023-03-01 | 美商凱麥拉醫療公司 | Cdk2降解劑及其用途 |
| JP2024526762A (ja) | 2021-07-12 | 2024-07-19 | インサイト・コーポレイション | Ｊａｋ阻害剤を調製するためのプロセス及び中間体 |
| WO2023018904A1 (en) | 2021-08-11 | 2023-02-16 | Concert Pharmaceuticals, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| JP2024534127A (ja) | 2021-08-25 | 2024-09-18 | ピク セラピューティクス， インコーポレイテッド | ｅＩＦ４Ｅ阻害剤及びその使用 |
| WO2023028238A1 (en) | 2021-08-25 | 2023-03-02 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| KR102718345B1 (ko) * | 2021-09-16 | 2024-10-17 | 광주과학기술원 | 신규한 트리아졸릴피롤로피리미딘 유도체 및 이의 용도 |
| WO2023042224A1 (en) * | 2021-09-18 | 2023-03-23 | Natco Pharma Limited | An improved process for the preparation of ruxolitinib phosphate |
| MX2024004993A (es) | 2021-10-25 | 2024-05-07 | Kymera Therapeutics Inc | Agentes degradantes de la proteina tirosina cinasa 2 (tyk2) y usos de los mismos. |
| EP4422635A4 (en) | 2021-10-29 | 2025-11-26 | Kymera Therapeutics Inc | IRAQ4 DEGRADATION AGENTS AND THEIR SYNTHESIS |
| IL312683A (en) | 2021-11-17 | 2024-07-01 | Altrubio Inc | Methods for using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell-mediated inflammatory diseases or cancer |
| WO2023102559A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN114044777B (zh) * | 2022-01-10 | 2022-04-19 | 南京佰麦生物技术有限公司 | 一种磷酸芦可替尼的制备方法 |
| EP4472967A2 (en) | 2022-01-31 | 2024-12-11 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN114456181A (zh) * | 2022-02-21 | 2022-05-10 | 浙江乐普药业股份有限公司 | 一种芦可替尼的制备方法 |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| EP4532470A1 (en) | 2022-05-25 | 2025-04-09 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| CN119677746A (zh) * | 2022-06-14 | 2025-03-21 | 因赛特公司 | Jak抑制剂的固体形式和其制备方法 |
| CN117384163A (zh) * | 2022-07-05 | 2024-01-12 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种含偕二氟基的化合物及其制备方法和用途 |
| EP4565568A1 (en) | 2022-08-02 | 2025-06-11 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| TW202416972A (zh) | 2022-08-02 | 2024-05-01 | 英商利米那生物科技有限公司 | 經取代之吡啶酮gpr84拮抗劑及其用途 |
| TW202415650A (zh) | 2022-08-02 | 2024-04-16 | 英商利米那生物科技有限公司 | 芳基-三唑基及相關gpr84拮抗劑及其用途 |
| WO2024028193A1 (en) | 2022-08-03 | 2024-02-08 | Medichem, S.A. | Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate |
| CN119032095A (zh) * | 2022-08-22 | 2024-11-26 | 印度颗粒有限公司 | 制备鲁索利替尼的改进方法 |
| US20240166654A1 (en) * | 2022-11-11 | 2024-05-23 | Zhejiang Ausun Pharmaceutical Co., Ltd. | Ruxolitinib crystal and pharmaceutical composition thereof |
| US20240208961A1 (en) | 2022-11-22 | 2024-06-27 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2024184926A1 (en) * | 2023-03-08 | 2024-09-12 | Aarti Pharmalabs Limited | Process for preparation of chiral ruxolitinib and salts thereof |
| WO2024187415A1 (en) * | 2023-03-15 | 2024-09-19 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising ruxolitinib |
| WO2024187416A1 (en) * | 2023-03-15 | 2024-09-19 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising ruxolitinib |
| US20240398810A1 (en) | 2023-05-21 | 2024-12-05 | Incyte Corporation | Topical ruxolitinib foam |
| EP4620470A3 (en) | 2023-06-23 | 2025-10-08 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4491175A1 (en) | 2023-07-10 | 2025-01-15 | Genepharm S.A. | A solid oral composition of ruxolitinib |
| WO2025052191A1 (en) | 2023-09-04 | 2025-03-13 | Granules India Limited | Improved process for the preparation of ruxolitinib and novel crystalline form thereof |
| IT202300018879A1 (it) | 2023-09-14 | 2025-03-14 | Chemelectiva S R L | Processo enzimatico per la preparazione di (r)-3-(4-bromo-1h-pirazol-1-il)-3- ciclopentilpropanenitrile, quale intermedio nella sintesi di ruxolitinib |
| WO2025062372A1 (en) | 2023-09-21 | 2025-03-27 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| US12364699B2 (en) | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| WO2025117642A1 (en) | 2023-12-01 | 2025-06-05 | Incyte Corporation | Ruxolitinib for treating hidradenitis suppurativa (hs) |
| EP4621803A1 (en) | 2024-03-22 | 2025-09-24 | Assistance Publique - Hôpitaux de Paris | Method for identifying patients in need for ici-induced myotoxicity treatment |
| WO2025207818A1 (en) * | 2024-03-27 | 2025-10-02 | Gilead Sciences, Inc. | Small molecule modulators of stat6 |
| US20250325664A1 (en) | 2024-04-22 | 2025-10-23 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
Family Cites Families (311)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985589A (en) * | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
| US3632836A (en) | 1968-10-25 | 1972-01-04 | Dow Chemical Co | Solid curable polyepoxides modified with hydrolyzed liquid polyepoxides |
| US3832460A (en) * | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| DE3220113A1 (de) * | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
| US4402832A (en) * | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
| US4404335A (en) | 1982-08-16 | 1983-09-13 | The Dow Chemical Company | Hydrolyzing epoxy resins in absence of solvent and in presence of oxalic acid and a phosphonium compound |
| US4548990A (en) * | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4498991A (en) * | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
| NL8403224A (nl) * | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
| US4921947A (en) | 1986-03-31 | 1990-05-01 | Eli Lilly And Company | Process for preparing macrolide derivatives |
| JPH0710876Y2 (ja) | 1989-08-31 | 1995-03-15 | 石垣機工株式会社 | スクリュープレスにおける脱水筒の洗浄装置 |
| KR0155955B1 (ko) * | 1989-10-11 | 1998-11-16 | 이따가끼 히로시 | 2 환성 피리미딘 유도체, 그의 제조방법 및 그를 유효성분으로 하는 의약제제 |
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| IT1258781B (it) * | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| FR2695126B1 (fr) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| JPH0710876A (ja) * | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| USH1439H (en) | 1993-10-18 | 1995-05-02 | The Dow Chemical Company | Method to increase the level of α-glycol in liquid epoxy resin |
| EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| US5856326A (en) * | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| WO1997002262A1 (en) | 1995-07-05 | 1997-01-23 | E.I. Du Pont De Nemours And Company | Fungicidal pyrimidinones |
| WO1997002266A1 (en) | 1995-07-06 | 1997-01-23 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
| US5630943A (en) * | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| CA2250232A1 (en) | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
| WO1997038664A2 (en) | 1996-04-18 | 1997-10-23 | Merck & Co., Inc. | A method of treating cancer |
| US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| AU3215197A (en) | 1996-05-30 | 1998-01-05 | Merck & Co., Inc. | A method of treating cancer |
| US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| JP2001524079A (ja) | 1997-04-07 | 2001-11-27 | メルク エンド カンパニー インコーポレーテッド | ガンの治療方法 |
| US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
| US6060038A (en) * | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| US5919779A (en) * | 1997-08-11 | 1999-07-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-Heteroaryl-dipyrido(2,3-B:3', 2'-F) azepines and their use in the prevention or treatment of HIV infection |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6232320B1 (en) * | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| JP2002517396A (ja) | 1998-06-04 | 2002-06-18 | アボット・ラボラトリーズ | 細胞接着阻害抗炎症性化合物 |
| DE69916833T2 (de) | 1998-06-19 | 2005-04-14 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-verbindungen |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| DE69942097D1 (de) | 1998-08-11 | 2010-04-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| US6713089B1 (en) * | 1998-09-10 | 2004-03-30 | Nycomed Danmark A/S | Quick release pharmaceutical compositions of drug substances |
| US6413419B1 (en) * | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
| FR2785196B1 (fr) * | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
| US6375839B1 (en) * | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| WO2000051614A1 (en) | 1999-03-03 | 2000-09-08 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6217895B1 (en) * | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) * | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| WO2000063168A1 (en) | 1999-04-16 | 2000-10-26 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| DE60013464T2 (de) | 1999-10-13 | 2005-09-15 | Banyu Pharmaceutical Co., Ltd. | Substituierte imidazolin-derivate |
| US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| SK287188B6 (sk) * | 1999-12-10 | 2010-02-08 | Pfizer Products Inc. | Pyrolo [2,3-d]pyrimidínová zlúčenina, jej použitie a farmaceutická kompozícia alebo kombinácia s jej obsahom |
| DZ3377A1 (fr) * | 1999-12-24 | 2001-07-05 | Aventis Pharma Ltd | Azaindoles |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) * | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| ATE250924T1 (de) * | 2000-04-07 | 2003-10-15 | Medidom Lab | Cyklosporin, hyaluronsäure und polysorbate enthaltenes augenarzneimittel |
| AU4878601A (en) | 2000-04-20 | 2001-11-07 | Mitsubishi Corporation | Aromatic amide compounds |
| EP1278748B1 (en) * | 2000-04-25 | 2011-03-23 | ICOS Corporation | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US7498304B2 (en) * | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| WO2001098344A2 (en) | 2000-06-16 | 2001-12-27 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| US6335342B1 (en) * | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| KR20030011106A (ko) * | 2000-06-23 | 2003-02-06 | 미쯔비시 웰 파마 가부시키가이샤 | 항종양 작용 강화제 |
| JP4068958B2 (ja) * | 2000-06-26 | 2008-03-26 | ファイザー・プロダクツ・インク | 免疫抑制剤としてのピロロ（２，３−ｄ）ピリミジン化合物 |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| AU2001278790A1 (en) | 2000-08-22 | 2002-03-04 | Hokuriku Seiyaku Co. Ltd | 1h-imidazopyridine derivatives |
| US20020111353A1 (en) * | 2000-12-05 | 2002-08-15 | Mark Ledeboer | Inhibitors of c-Jun N-terminal kinases (JNK) and other protein kinases |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| EP1351936A1 (en) | 2001-01-15 | 2003-10-15 | Glaxo Group Limited | Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression |
| WO2002060492A1 (en) | 2001-01-30 | 2002-08-08 | Cytopia Pty Ltd | Methods of inhibiting kinases |
| AU2002308748A1 (en) | 2001-05-16 | 2002-11-25 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| CA2455181C (en) * | 2001-08-01 | 2010-04-06 | Merck & Co., Inc. | Benzimidazo[4,5-f]isoquinolinone derivatives |
| IL160915A0 (en) | 2001-09-19 | 2004-08-31 | Aventis Pharma Sa | Indolizines inhibiting kinase proteins |
| US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
| ES2269793T3 (es) | 2001-10-30 | 2007-04-01 | Novartis Ag | Derivados de estaurospina como inhibidores de la actividad de tirosina quinasa receptora flt3. |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| CA2468942A1 (en) * | 2001-11-30 | 2003-06-12 | Teijin Limited | Process for producing 5-(3-cyanophenyl)-3-formylbenzoic acid compound |
| GT200200234A (es) | 2001-12-06 | 2003-06-27 | Compuestos cristalinos novedosos | |
| US6995144B2 (en) * | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| AU2003237807B2 (en) | 2002-04-15 | 2008-10-23 | Rb Health (Us) Llc | Sustained release of guaifenesin combination drugs |
| TW200403058A (en) * | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| EP1506189A1 (en) * | 2002-04-26 | 2005-02-16 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
| WO2003092595A2 (en) | 2002-05-02 | 2003-11-13 | Merck & Co., Inc | Tyrosine kinase inhibitors |
| WO2003094888A1 (en) * | 2002-05-07 | 2003-11-20 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| DE60317198T2 (de) * | 2002-05-23 | 2008-12-04 | Cytopia Research Pty. Ltd., Richmond | Proteinkinaseinhibitoren |
| TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
| WO2004003026A1 (ja) * | 2002-06-26 | 2004-01-08 | Idemitsu Kosan Co., Ltd. | 共重合体水素添加物、その製造方法及びそれを用いたホットメルト接着剤組成物 |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0215844D0 (en) * | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| US20060004010A1 (en) * | 2002-07-10 | 2006-01-05 | Hiromu Habashita | Ccr4 antagonist and medical use thereof |
| PL374700A1 (pl) | 2002-09-20 | 2005-10-31 | Alcon, Inc. | Zastosowanie inhibitorów syntezy cytokiny do leczenia zespołu suchego oka |
| US20040204404A1 (en) * | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| US7259161B2 (en) | 2002-11-04 | 2007-08-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US20040099204A1 (en) | 2002-11-25 | 2004-05-27 | Nestor John J. | Sheet, page, line, position marker |
| WO2004047843A1 (en) | 2002-11-26 | 2004-06-10 | Pfizer Products Inc. | Method of treatment of transplant rejection |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TWI335819B (en) * | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| TW200418806A (en) | 2003-01-13 | 2004-10-01 | Fujisawa Pharmaceutical Co | HDAC inhibitor |
| US7444183B2 (en) * | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
| WO2004072063A1 (en) | 2003-02-07 | 2004-08-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| SE0301372D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| SE0301373D0 (sv) | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
| US20050043346A1 (en) * | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| JP5010917B2 (ja) | 2003-08-29 | 2012-08-29 | エグゼリクシス， インコーポレイテッド | ｃ−Ｋｉｔ調節因子および使用方法 |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| ATE490771T1 (de) * | 2003-10-24 | 2010-12-15 | Santen Pharmaceutical Co Ltd | Therapeutisches mittel für keratokonjunktive erkrankungen |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| JP2007512316A (ja) | 2003-11-25 | 2007-05-17 | ファイザー・プロダクツ・インク | アテローム性動脈硬化症の治療方法 |
| BRPI0417803A (pt) | 2003-12-17 | 2007-04-10 | Pfizer Prod Inc | método de tratamento de rejeição de transplantes |
| WO2005062795A2 (en) | 2003-12-19 | 2005-07-14 | Plexxikon, Inc. | Compounds and methods for development of ret modulators |
| TW200528450A (en) * | 2003-12-19 | 2005-09-01 | Schering Corp | Thiadiazoles as cxc-and cc-chemokine receptor ligands |
| PL1706385T3 (pl) | 2003-12-23 | 2011-03-31 | Astex Therapeutics Ltd | Pochodne pirazolu jako modulatory kinazy białkowej |
| US20050187389A1 (en) * | 2004-01-13 | 2005-08-25 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| CA2559285A1 (en) | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| EP1730146B1 (en) | 2004-03-30 | 2011-05-04 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of jak and other protein kinases |
| CA2563699C (en) | 2004-04-23 | 2014-03-25 | Exelixis, Inc. | Kinase modulators and method of use |
| WO2005105988A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Crystal structure of human jak3 kinase domain complex and binding pockets thereof |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| EP1755680A1 (en) | 2004-05-03 | 2007-02-28 | Novartis AG | Combinations comprising a s1p receptor agonist and a jak3 kinase inhibitor |
| US20060074102A1 (en) | 2004-05-14 | 2006-04-06 | Kevin Cusack | Kinase inhibitors as therapeutic agents |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| MY144044A (en) | 2004-06-10 | 2011-07-29 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| WO2006001463A1 (ja) * | 2004-06-23 | 2006-01-05 | Ono Pharmaceutical Co., Ltd. | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| CA2572058A1 (en) | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
| US7138423B2 (en) * | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| FR2873691B1 (fr) * | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| CN101006186A (zh) | 2004-08-23 | 2007-07-25 | 财团法人牧岩生命工学研究所 | 用于检测sars冠状病毒的引物和探针，包括该引物和/或探针的试剂盒及其检测方法 |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| PT1802625E (pt) * | 2004-10-13 | 2008-08-06 | Hoffmann La Roche | Pirazolobenzodiazepinas di-substituídas, úteis como inibidores de cdc2 e de angiogénese e para o tratamento de cancro da mama, do cólon, do pulmão e da próstata |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| KR20070090172A (ko) * | 2004-11-04 | 2007-09-05 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘 |
| WO2006056399A2 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of jak inhibitors and at least one of bcr-abl, flt-3, fak or raf kinase inhibitors |
| US7517870B2 (en) * | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| WO2006065916A1 (en) * | 2004-12-14 | 2006-06-22 | Alcon, Inc. | Method of treating dry eye disorders using 13(s)-hode and its analogs |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| CA2595574A1 (en) | 2005-01-20 | 2006-07-27 | Pfizer Limited. | Chemical compounds |
| US8633205B2 (en) * | 2005-02-03 | 2014-01-21 | Vertex Pharmaceuticals Incorporated | Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases |
| US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| CN101500574A (zh) | 2005-03-15 | 2009-08-05 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| AU2006232105A1 (en) | 2005-04-05 | 2006-10-12 | Pharmacopeia, Inc. | Purine and imidazopyridine derivatives for immunosuppression |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP2354139A1 (en) * | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| EP1904457B1 (en) | 2005-06-08 | 2017-09-06 | Rigel Pharmaceuticals, Inc. | Compositions and methods for inhibition of the jak pathway |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| NZ565255A (en) | 2005-06-22 | 2010-04-30 | Plexxikon Inc | Pyrrolo[2,3-b] pyridine derivatives as protein kinase inhibitors |
| EP2251341A1 (en) | 2005-07-14 | 2010-11-17 | Astellas Pharma Inc. | Heterocyclic Janus kinase 3 inhibitors |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| WO2007025090A2 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase |
| US20070149506A1 (en) | 2005-09-22 | 2007-06-28 | Arvanitis Argyrios G | Azepine inhibitors of Janus kinases |
| CA2623032A1 (en) | 2005-09-30 | 2007-04-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| US20070128633A1 (en) | 2005-10-11 | 2007-06-07 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
| PL1937664T3 (pl) | 2005-10-14 | 2011-11-30 | Sumitomo Chemical Co | Związki hydrazydowe i ich zastosowanie jako pestycydy |
| ES2391783T3 (es) | 2005-10-28 | 2012-11-29 | Astrazeneca Ab | Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer |
| KR101467723B1 (ko) * | 2005-11-01 | 2014-12-03 | 탈자진 인코포레이티드 | 키나제의 비-아릴 메타-피리미딘 억제제 |
| WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| US20130137681A1 (en) * | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| SI1966202T1 (sl) * | 2005-12-13 | 2012-01-31 | Incyte Corp | S heteroarilom substituirani pirolo (2,3-b)piridini in pirolo (2,3-b)pirimidini kot zaviralci janus kinaze |
| JP2009521504A (ja) | 2005-12-22 | 2009-06-04 | スミスクライン・ビーチャム・コーポレイション | Ａｋｔ活性阻害剤 |
| JP5140600B2 (ja) * | 2005-12-23 | 2013-02-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | オーロラキナーゼのアザインドール阻害薬 |
| JP4643455B2 (ja) | 2006-01-12 | 2011-03-02 | 株式会社ユニバーサルエンターテインメント | 遊技システム |
| AU2007207533B8 (en) | 2006-01-17 | 2012-06-28 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of Janus kinases |
| US20070208053A1 (en) * | 2006-01-19 | 2007-09-06 | Arnold Lee D | Fused heterobicyclic kinase inhibitors |
| WO2007090141A2 (en) | 2006-02-01 | 2007-08-09 | Smithkline Beecham Corporation | Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| US20070202172A1 (en) | 2006-02-24 | 2007-08-30 | Tomer Gold | Metoprolol succinate E.R. tablets and methods for their preparation |
| RU2008140144A (ru) * | 2006-03-10 | 2010-04-20 | Оно Фармасьютикал Ко., Лтд. (Jp) | Азотосодержащее гетероциклическое производное и фармацевтическое средство, включающее такое производное в качестве активного ингредиента |
| JP5099005B2 (ja) * | 2006-04-03 | 2012-12-12 | アステラス製薬株式会社 | ヘテロ化合物 |
| EP2001884A1 (en) | 2006-04-05 | 2008-12-17 | Vertex Pharmaceuticals, Inc. | Deazapurines useful as inhibitors of janus kinases |
| EP2059515A2 (en) | 2006-04-12 | 2009-05-20 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| AU2007252994A1 (en) | 2006-05-18 | 2007-11-29 | Bayer Healthcare Ag | Pharmaceutical compositions comprising implitapide and methods of using same |
| US7691811B2 (en) * | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| JO3235B1 (ar) | 2006-05-26 | 2018-03-08 | Astex Therapeutics Ltd | مركبات بيررولوبيريميدين و استعمالاتها |
| NZ573174A (en) | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| EP2044061A2 (en) * | 2006-07-20 | 2009-04-08 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8492378B2 (en) * | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| CA2660560A1 (en) * | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Pyrazine compounds, their use and methods of preparation |
| JP2010502675A (ja) | 2006-09-08 | 2010-01-28 | ノバルティス アクチエンゲゼルシャフト | リンパ球相互作用が介在する疾患または障害を処置するために有用なｎ−ビアリール（ヘテロ）アリールスルホンアミド誘導体 |
| WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
| AR063141A1 (es) * | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2- ( benzimidazolil ) purina 8- sustituida para inmunosupresion |
| TW200831104A (en) | 2006-10-04 | 2008-08-01 | Pharmacopeia Inc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| NZ576234A (en) * | 2006-11-06 | 2011-06-30 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20080119496A1 (en) * | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| KR101532256B1 (ko) | 2006-11-22 | 2015-06-29 | 인사이트 코포레이션 | 키나제 억제제로서의 이미다조트리아진 및 이미다조피리미딘 |
| WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
| NZ577111A (en) * | 2006-12-15 | 2012-05-25 | Abbott Lab | Novel oxadiazole compounds |
| AU2007338793B2 (en) | 2006-12-20 | 2012-05-03 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| CA2672438A1 (en) | 2006-12-20 | 2008-07-03 | Amgen Inc. | Substituted heterocycles and methods of use |
| US8389014B2 (en) | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| ES2415863T3 (es) | 2006-12-22 | 2013-07-29 | Incyte Corporation | Heterociclos sustituidos como inhibidores de Janus Quinasas |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| MX2009010728A (es) | 2007-04-03 | 2009-10-26 | Array Biopharma Inc | Compuestos de imidazo[1,2-a]piridina como inhibidores de la tirosina-cinasa repectora. |
| US8188178B2 (en) | 2007-05-07 | 2012-05-29 | 3M Innovative Properties Company | Cold shrinkable article including an epichlorohydrin composition |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| US8653262B2 (en) | 2007-05-31 | 2014-02-18 | Boehringer Ingelheim International Gmbh | CCR2 receptor antagonists and uses thereof |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| EP4606378A3 (en) | 2007-06-13 | 2025-11-05 | Incyte Holdings Corporation | Salts of the janus kinase inhibitor (r)-3-( 4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3- cyclopentylprop anenitrile |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| BRPI0813553A2 (pt) | 2007-07-11 | 2017-05-09 | Pfizer | composições farmacêuticas e métodos para tratamento de distúrbios do olho seco |
| WO2009016460A2 (en) * | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| WO2009064486A2 (en) | 2007-11-15 | 2009-05-22 | Musc Foundation For Research Development | Inhibitors of pim protein kinases, compositions, and methods for treating cancer |
| JP5480813B2 (ja) | 2007-11-16 | 2014-04-23 | インサイト・コーポレイション | Ｊａｎｕｓキナーゼ阻害剤としての置換複素環 |
| GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| NZ586610A (en) * | 2008-01-18 | 2012-08-31 | Acad Of Science Czech Republic | Novel cytostatic 7-deazapurine nucleosides |
| UA106037C2 (uk) | 2008-02-04 | 2014-07-25 | Мерк'Юрі Терап'Ютікс, Інк. | Модулятори ampk (амф-активованої протеїнкінази) |
| UY31679A1 (es) | 2008-03-03 | 2009-09-30 | Inhibidores de cinasa pim y metodos para su uso | |
| SG191660A1 (en) | 2008-03-11 | 2013-07-31 | Incyte Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| BRPI0908906A2 (pt) | 2008-03-21 | 2019-09-24 | Novartis Ag | compostos heterocíclicos e usos dos mesmos |
| JP2011525892A (ja) | 2008-06-18 | 2011-09-29 | メルク・シャープ・エンド・ドーム・コーポレイション | Ｊａｎｕｓキナーゼの阻害剤 |
| JP2011526302A (ja) | 2008-06-26 | 2011-10-06 | アンテリオス， インコーポレイテッド | 経皮送達 |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
| US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| ES2467109T3 (es) | 2008-08-20 | 2014-06-11 | Zoetis Llc | Compuestos de pirrolo[2,3-d]pirimidina |
| BRPI0918268B1 (pt) | 2008-09-02 | 2021-08-03 | Novartis Ag | Derivados de picolinamida, seu uso, e composição farmacêutica |
| CA2735782A1 (en) | 2008-09-02 | 2010-03-11 | Novartis Ag | Heterocyclic pim-kinase inhibitors |
| KR20110058866A (ko) | 2008-09-02 | 2011-06-01 | 노파르티스 아게 | 비시클릭 키나제 억제제 |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| US20110183958A1 (en) | 2008-10-17 | 2011-07-28 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| JOP20190230A1 (ar) | 2009-01-15 | 2017-06-16 | Incyte Corp | طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| UA106078C2 (uk) * | 2009-05-22 | 2014-07-25 | Інсайт Корпорейшн | 3-[4-(7H-ПІРОЛО[2,3-d]ПІРИМІДИН-4-ІЛ)-1H-ПІРАЗОЛ-1-ІЛ]ОКТАН- АБО ГЕПТАННІТРИЛ ЯК JAK-ІНГІБІТОРИ |
| AU2010249380B2 (en) | 2009-05-22 | 2015-08-20 | Incyte Holdings Corporation | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as Janus kinase inhibitors |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| TW201105674A (en) | 2009-07-08 | 2011-02-16 | Leo Pharma As | Novel JAK receptor and protein tyrosine kinase inhibitors and pharmaceutical use thereof |
| WO2011025685A1 (en) | 2009-08-24 | 2011-03-03 | Merck Sharp & Dohme Corp. | Jak inhibition blocks rna interference associated toxicities |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| TW201113285A (en) * | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| WO2011029802A1 (en) | 2009-09-08 | 2011-03-17 | F. Hoffmann-La Roche Ag | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| CN105541847B (zh) | 2009-10-09 | 2019-08-16 | 因西特控股公司 | 3-(4-(7H-吡咯并[2,3-d]嘧啶-4-基)-1H-吡唑-1-基)-3-环戊基丙腈的羟基衍生物、酮基衍生物和葡糖苷酸衍生物 |
| NZ598907A (en) | 2009-10-20 | 2014-03-28 | Cellzome Ltd | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| US8671402B2 (en) | 2009-11-09 | 2014-03-11 | Bank Of America Corporation | Network-enhanced control of software updates received via removable computer-readable medium |
| EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
| WO2011066374A2 (en) | 2009-11-24 | 2011-06-03 | Alder Biopharmaceuticals, Inc. | Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever |
| US20130129675A1 (en) | 2009-12-04 | 2013-05-23 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| EP2513114B1 (en) | 2009-12-18 | 2014-04-02 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| CN102712640A (zh) | 2010-01-12 | 2012-10-03 | 弗·哈夫曼-拉罗切有限公司 | 三环杂环化合物、其组合物和应用方法 |
| WO2011097087A1 (en) | 2010-02-05 | 2011-08-11 | Pfizer Inc. | Pyrrolo [ 2, 3 - d] pyrimidine urea compounds as jak inhibitors |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| US20110207754A1 (en) * | 2010-02-18 | 2011-08-25 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
| SI2545045T1 (sl) | 2010-03-10 | 2016-05-31 | Incyte Holdings Corporation | Derivati piperidin-4-ila kot zaviralci JAK1 |
| CA2796388A1 (en) | 2010-04-14 | 2011-10-20 | Array Biopharma Inc. | 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| MX338228B (es) | 2010-05-21 | 2016-04-08 | Incyte Corp | Formulacion topica para inhibidor de cinasas janus (jak). |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| WO2012003457A1 (en) | 2010-07-01 | 2012-01-05 | Mtm Research Llc | Anti-fibroblastic fluorochemical emulsion therapies |
| US20130237493A1 (en) | 2010-09-30 | 2013-09-12 | Portola Pharmaceuticals, Inc. | Combination therapy of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| US9034884B2 (en) * | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| US8933085B2 (en) | 2010-11-19 | 2015-01-13 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| EP2646029A4 (en) | 2010-12-03 | 2014-06-18 | Ym Biosciences Australia Pty | TREATMENT OF JAK2-MEDIATED DISEASES |
| PT2675451E (pt) * | 2011-02-18 | 2015-10-16 | Incyte Corp | Terapia de combinação com inibidores mtor/jak |
| CN102247368B (zh) | 2011-05-19 | 2013-05-29 | 安徽永生堂药业有限责任公司 | 一种复方阿伐斯汀缓释片及其制备方法 |
| CN102218042A (zh) | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
| WO2012177606A1 (en) * | 2011-06-20 | 2012-12-27 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| US9358229B2 (en) * | 2011-08-10 | 2016-06-07 | Novartis Pharma Ag | JAK PI3K/mTOR combination therapy |
| TW201313721A (zh) * | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| US9193733B2 (en) | 2012-05-18 | 2015-11-24 | Incyte Holdings Corporation | Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| IN2014DN10670A (OSRAM) | 2012-06-15 | 2015-08-28 | Concert Pharmaceuticals Inc | |
| US20150246043A1 (en) | 2012-07-27 | 2015-09-03 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
| CN102772384A (zh) | 2012-08-07 | 2012-11-14 | 四川百利药业有限责任公司 | 一种盐酸米诺环素缓释片及其制备方法 |
| WO2014036016A1 (en) | 2012-08-31 | 2014-03-06 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
| WO2014071031A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| IL297429A (en) | 2012-11-15 | 2022-12-01 | Incyte Holdings Corp | Sustained release dosage forms of roxolitinib |
| PT3489239T (pt) | 2013-03-06 | 2021-12-17 | Incyte Holdings Corp | Processos e intermediários para a preparação de um inibidor de jak |
| TR201905814T4 (tr) | 2013-05-17 | 2019-05-21 | Incyte Corp | Jak inhibitörü olarak bipirazol tuzu. |
| CN114010611B (zh) | 2013-08-07 | 2023-11-28 | 因赛特控股公司 | Jak1抑制剂的持续释放剂型 |
| AU2014309017A1 (en) | 2013-08-20 | 2016-03-10 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated C-reactive protein levels |
| WO2015131031A1 (en) | 2014-02-28 | 2015-09-03 | Incyte Corporation | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| EP3795152A1 (en) | 2014-04-08 | 2021-03-24 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitor |
| JP2017514832A (ja) | 2014-04-30 | 2017-06-08 | インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｋ１抑制剤を調製する方法及びその新しい形態 |
| EP4233870A3 (en) | 2014-05-28 | 2024-01-24 | Onco Tracker, Inc. | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| EP3921318A1 (en) | 2019-02-06 | 2021-12-15 | Concert Pharmaceuticals Inc. | Process for preparing enantiomerically enriched jak inhibitors |
-
2006
- 2006-12-12 SI SI200631209T patent/SI1966202T1/sl unknown
- 2006-12-12 EA EA200870048A patent/EA019504B1/ru active Protection Beyond IP Right Term
- 2006-12-12 SG SG10201506912RA patent/SG10201506912RA/en unknown
- 2006-12-12 EP EP11152708.1A patent/EP2348023B9/en active Active
- 2006-12-12 RS RS20150513A patent/RS54181B9/sr unknown
- 2006-12-12 EP EP11152677.8A patent/EP2343299B9/en active Active
- 2006-12-12 SI SI200632020A patent/SI2343299T1/sl unknown
- 2006-12-12 PT PT111527149T patent/PT2474545T/pt unknown
- 2006-12-12 RS RS20170047A patent/RS55576B1/sr unknown
- 2006-12-12 TW TW103136068A patent/TWI553008B/zh active
- 2006-12-12 HU HUE16197502A patent/HUE041382T2/hu unknown
- 2006-12-12 RS RS20181405A patent/RS58113B1/sr unknown
- 2006-12-12 PL PL11152730T patent/PL2455382T3/pl unknown
- 2006-12-12 ES ES11152723.0T patent/ES2612196T3/es active Active
- 2006-12-12 MY MYPI20082099A patent/MY159449A/en unknown
- 2006-12-12 HU HUE11152708A patent/HUE025173T2/hu unknown
- 2006-12-12 ES ES11152714.9T patent/ES2612489T3/es active Active
- 2006-12-12 AU AU2006326548A patent/AU2006326548B2/en active Active
- 2006-12-12 PT PT06839328T patent/PT1966202E/pt unknown
- 2006-12-12 US US11/637,545 patent/US7598257B2/en active Active
- 2006-12-12 BR BRPI0619817A patent/BRPI0619817B8/pt active IP Right Grant
- 2006-12-12 SG SG10202003901UA patent/SG10202003901UA/en unknown
- 2006-12-12 DK DK11152714.9T patent/DK2474545T3/en active
- 2006-12-12 TW TW107113620A patent/TWI664182B/zh active
- 2006-12-12 DK DK16197502.4T patent/DK3184526T3/en active
- 2006-12-12 SI SI200632294T patent/SI3184526T1/sl unknown
- 2006-12-12 MY MYPI2013002970A patent/MY162590A/en unknown
- 2006-12-12 PL PL16197502T patent/PL3184526T3/pl unknown
- 2006-12-12 EP EP16197502.4A patent/EP3184526B1/en active Active
- 2006-12-12 SI SI200632137A patent/SI2474545T1/sl unknown
- 2006-12-12 SI SI200632135A patent/SI2426129T1/sl unknown
- 2006-12-12 UA UAA201115478A patent/UA116187C2/uk unknown
- 2006-12-12 DK DK06839328.9T patent/DK1966202T3/da active
- 2006-12-12 CN CN201310059187.8A patent/CN103214484B/zh active Active
- 2006-12-12 TW TW101121442A patent/TWI468162B/zh active
- 2006-12-12 DK DK11152677.8T patent/DK2343299T3/en active
- 2006-12-12 KR KR1020127024525A patent/KR101391900B1/ko active Active
- 2006-12-12 HU HUE11152723A patent/HUE030235T2/en unknown
- 2006-12-12 SG SG2012014957A patent/SG179430A1/en unknown
- 2006-12-12 EP EP11152714.9A patent/EP2474545B1/en active Active
- 2006-12-12 LT LTEP11152714.9T patent/LT2474545T/lt unknown
- 2006-12-12 TW TW095146502A patent/TWI410407B/zh active
- 2006-12-12 CN CN201310058988.2A patent/CN103214483B/zh active Active
- 2006-12-12 EP EP20206996.9A patent/EP3838903B1/en active Active
- 2006-12-12 PL PL11152714T patent/PL2474545T3/pl unknown
- 2006-12-12 UA UAA200809072A patent/UA98449C2/ru unknown
- 2006-12-12 LT LTEP16197502.4T patent/LT3184526T/lt unknown
- 2006-12-12 PL PL11152677.8T patent/PL2343299T3/pl unknown
- 2006-12-12 ES ES11152674.5T patent/ES2543903T3/es active Active
- 2006-12-12 NZ NZ569015A patent/NZ569015A/en unknown
- 2006-12-12 HU HUE11152730A patent/HUE030418T2/en unknown
- 2006-12-12 ES ES18191992T patent/ES2867505T3/es active Active
- 2006-12-12 PT PT111526778T patent/PT2343299E/pt unknown
- 2006-12-12 RS RS20160052A patent/RS54683B1/sr unknown
- 2006-12-12 RS RS20170081A patent/RS55634B1/sr unknown
- 2006-12-12 PL PL11152708T patent/PL2348023T3/pl unknown
- 2006-12-12 LT LTEP11152730.5T patent/LT2455382T/lt unknown
- 2006-12-12 HU HUE11152677A patent/HUE028588T2/hu unknown
- 2006-12-12 PT PT111527230T patent/PT2426129T/pt unknown
- 2006-12-12 EP EP11152674.5A patent/EP2343298B9/en active Active
- 2006-12-12 ES ES16197502T patent/ES2700433T3/es active Active
- 2006-12-12 ES ES11152730.5T patent/ES2611588T3/es active Active
- 2006-12-12 ME MEP-2011-199A patent/ME01312B/me unknown
- 2006-12-12 PT PT111527081T patent/PT2348023E/pt unknown
- 2006-12-12 DK DK11152723.0T patent/DK2426129T3/en active
- 2006-12-12 EA EA201691294A patent/EA036785B1/ru active Protection Beyond IP Right Term
- 2006-12-12 NZ NZ778831A patent/NZ778831A/en unknown
- 2006-12-12 RS RS20110571A patent/RS52101B/sr unknown
- 2006-12-12 ES ES11152708.1T patent/ES2543904T3/es active Active
- 2006-12-12 EP EP11152730.5A patent/EP2455382B1/en active Active
- 2006-12-12 DK DK11152730.5T patent/DK2455382T3/da active
- 2006-12-12 EP EP18191992.9A patent/EP3466953B1/en active Active
- 2006-12-12 TW TW105120803A patent/TWI630207B/zh active
- 2006-12-12 PT PT16197502T patent/PT3184526T/pt unknown
- 2006-12-12 SI SI200631956T patent/SI2348023T1/sl unknown
- 2006-12-12 RS RS20170079A patent/RS55632B1/sr unknown
- 2006-12-12 EP EP06839328A patent/EP1966202B1/en active Active
- 2006-12-12 HR HR20110903T patent/HRP20110903T1/hr unknown
- 2006-12-12 ES ES11152677.8T patent/ES2561507T3/es active Active
- 2006-12-12 JP JP2008545733A patent/JP5017278B2/ja active Active
- 2006-12-12 PL PL06839328T patent/PL1966202T3/pl unknown
- 2006-12-12 MX MX2015003466A patent/MX346183B/es unknown
- 2006-12-12 AT AT06839328T patent/ATE525374T1/de active
- 2006-12-12 ES ES20206996T patent/ES2970354T3/es active Active
- 2006-12-12 KR KR1020127024523A patent/KR101324737B1/ko active Active
- 2006-12-12 ES ES06839328T patent/ES2373688T3/es active Active
- 2006-12-12 EA EA201200132A patent/EA035795B1/ru active Protection Beyond IP Right Term
- 2006-12-12 TW TW103117669A patent/TW201434835A/zh unknown
- 2006-12-12 LT LTEP11152723.0T patent/LT2426129T/lt unknown
- 2006-12-12 EP EP11152723.0A patent/EP2426129B1/en active Active
- 2006-12-12 PL PL11152723T patent/PL2426129T3/pl unknown
- 2006-12-12 HU HUE11152714A patent/HUE032337T2/en unknown
- 2006-12-12 SI SI200632133A patent/SI2455382T1/sl unknown
- 2006-12-12 KR KR1020117029741A patent/KR101218214B1/ko active Active
- 2006-12-12 DK DK11152708.1T patent/DK2348023T5/da active
- 2006-12-12 WO PCT/US2006/047369 patent/WO2007070514A1/en not_active Ceased
- 2006-12-12 CN CN201310058991.4A patent/CN103254190B/zh active Active
- 2006-12-12 CA CA2632466A patent/CA2632466C/en active Active
- 2006-12-12 PT PT111527305T patent/PT2455382T/pt unknown
- 2006-12-12 CN CNA2006800527507A patent/CN101448826A/zh not_active Withdrawn
- 2006-12-13 AR ARP060105499A patent/AR057995A1/es active IP Right Grant
-
2008
- 2008-06-05 IL IL192019A patent/IL192019A/en active IP Right Grant
- 2008-06-12 US US12/138,082 patent/US8415362B2/en active Active
- 2008-06-12 CR CR10065A patent/CR10065A/es unknown
- 2008-06-12 ZA ZA2008/05165A patent/ZA200805165B/en unknown
- 2008-06-13 EC EC2008008540A patent/ECSP088540A/es unknown
- 2008-07-11 KR KR1020087017011A patent/KR101216055B1/ko active Active
-
2009
- 2009-08-27 US US12/549,170 patent/US8541425B2/en active Active
-
2011
- 2011-03-30 US US13/076,176 patent/US8946245B2/en active Active
- 2011-03-30 US US13/076,220 patent/US8530485B2/en active Active
- 2011-09-05 JP JP2011192962A patent/JP5710430B2/ja active Active
- 2011-12-20 CY CY20111101270T patent/CY1112762T1/el unknown
-
2012
- 2012-03-08 EC ECSP12008540 patent/ECSP12008540A/es unknown
-
2013
- 2013-01-09 LT LTPA2013002C patent/LTPA2013002I1/lt unknown
- 2013-01-18 LU LU92137C patent/LU92137I2/fr unknown
- 2013-01-21 FR FR13C0007C patent/FR13C0007I2/fr active Active
- 2013-02-15 CY CY2013006C patent/CY2013006I1/el unknown
- 2013-02-19 BE BE2013C014C patent/BE2013C014I2/fr unknown
- 2013-09-06 US US14/020,505 patent/US9206187B2/en active Active
- 2013-09-20 US US14/033,039 patent/US8933086B2/en active Active
- 2013-10-03 CR CR20130506A patent/CR20130506A/es unknown
- 2013-12-17 JP JP2013260480A patent/JP5876026B2/ja active Active
-
2014
- 2014-04-08 IL IL231992A patent/IL231992A/en active IP Right Grant
- 2014-05-12 US US14/274,948 patent/US9079912B2/en active Active
-
2015
- 2015-05-13 US US14/711,576 patent/US20150238492A1/en not_active Abandoned
- 2015-07-06 JP JP2015135307A patent/JP6138865B2/ja active Active
- 2015-07-31 CY CY20151100673T patent/CY1116574T1/el unknown
- 2015-08-06 HR HRP20150837TT patent/HRP20150837T2/hr unknown
-
2016
- 2016-02-02 HR HRP20160112TT patent/HRP20160112T1/hr unknown
- 2016-06-03 US US15/173,057 patent/US9662335B2/en active Active
- 2016-08-10 US US15/233,652 patent/US9814722B2/en active Active
- 2016-11-13 IL IL248938A patent/IL248938A0/en unknown
- 2016-11-21 US US15/356,957 patent/US9974790B2/en active Active
-
2017
- 2017-01-19 HR HRP20170090TT patent/HRP20170090T1/hr unknown
- 2017-01-20 CY CY20171100089T patent/CY1118506T1/el unknown
- 2017-01-30 CY CY20171100130T patent/CY1118724T1/el unknown
- 2017-02-01 HR HRP20170162TT patent/HRP20170162T1/hr unknown
- 2017-02-07 HR HRP20170200TT patent/HRP20170200T1/hr unknown
- 2017-02-08 CY CY20171100171T patent/CY1118607T1/el unknown
- 2017-04-25 CY CY2017015C patent/CY2017015I2/el unknown
- 2017-04-25 FR FR17C1013C patent/FR17C1013I2/fr active Active
- 2017-04-25 LT LTPA2017012C patent/LTPA2017012I1/lt unknown
- 2017-04-25 HU HUS1700017C patent/HUS1700017I1/hu unknown
-
2018
- 2018-04-23 US US15/960,069 patent/US10398699B2/en active Active
- 2018-11-01 US US16/177,602 patent/US10639310B2/en active Active
- 2018-11-16 HR HRP20181912TT patent/HRP20181912T1/hr unknown
- 2018-12-27 CY CY20181101401T patent/CY1121202T1/el unknown
-
2020
- 2020-03-17 US US16/821,624 patent/US11331320B2/en active Active
-
2022
- 2022-03-08 US US17/689,510 patent/US11744832B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11331320B2 (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | |
| US20130137681A1 (en) | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | |
| AU2025200056B2 (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | |
| AU2020294336B2 (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | |
| HK40051731A (en) | Pyrrolo[2,3-d]pyrimidine derivative as janus kinase inhibitor | |
| HK1160115B (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | |
| HK1240224A1 (en) | Pyrrolo[2,3-d]pyrimidine derivatives as janus kinase inhibitor | |
| HK1160137B (en) | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |